美国专利US20010002411A1 Medical devices comprising ionically and non-ionically crosslinked polymer hydrogels having improved

专利PDF首页>>美国专利

专利附录

专利说明

权利要求

类似技术

同族专利

引用文献

法律状态

优先权

专利摘要:
Shaped-medical devices, e.g. stents, having improved mechanical properties and structural integrity are disclosed. The devices comprise shaped polymeric hydrogels which are both tonically and non-ionically crosslinked and which exhibit improved structural integrity after selective removal of the crosslinking ions. Process for making such devices are also disclosed wherein an ionically crosslinkable polymer is both ionically and non-ionically crosslinked to form a shaped medical device. When implanted in the body, selective in-vivo stripping of the crosslinking ions produces a softer, more flexible implant having improved structural integrity.
公开号:US20010002411A1
申请号:US09/757,396
申请日:2001-01-08
公开日:2001-05-31
发明作者:John Ronan；Samuel Thompson
申请人:Ronan John A.；Thompson Samuel A.；
IPC主号:A61M27-008

专利说明:
[0001] 1. Field of the Invention [0001]
[0002] This invention relates to medical devices comprising polymer hydrogels having improved mechanical properties. [0002]
[0003] 2. Description of Related Art [0003]
[0004] Medical devices adapted for implant into the body to facilitate the flow of bodily fluids, to serve as vascular grafts or for other purposes have been developed. Typically, these devices include stents, catheters or cannulas, plugs, constrictors, tissue or biological encapsulants and the like. [0004]
[0005] Typically, many of these devices used as implants are made of durable, non-degradable plastic materials such as polyurethanes, polyacrylates, silicone polymers and the like, or more preferably from biodegradable polymers which remain stable in-vivo for a period of time but eventually biodegrade in-vivo into small molecules which are removed by the body by normal elimination in the urine or feces. [0005]
[0006] Typical of such biodegradable polymers are polyesters, polyanhydrides and polyorthoesters which undergo hydrolytic chain cleavage, as disclosed in U.S. Pat. No. 5,085,629; crosslinked polysaccharide hydrogel polymers as disclosed in EPA 0507604 A-2 and U.S. Pat. No. 5,057,606 and other tonically crosslinked hydrogels as disclosed in U.S. Pat. Nos. 4,941,870, 4,286,341 and 4,878,907. [0006]
[0007] EPA 0645150 A-1 describes hydrogel medical devices prepared from ionically crosslinked anionic polymers, e.g. polysaccharides such as calcium alginate or ionically crosslinked cationic polymers such as chitosan, cationic guar, cationic starch and polyethylene amine. These devices are adapted for more rapid in-vivo disintegration upon the administration of a chemical trigger material which displaces crosslinking ions. [0007]
[0008] Hydrogels offer excellent biocompatibility and have been shown to have reduced tendency for inducing thrombosis, encrustation, and inflammation. Unfortunately, the use of hydrogels in biomedical device applications has often been hindered by poor mechanical performance. Although many medical device applications exist where minimal stresses are encountered by the device in-vivo, most applications require that the device survive high stresses during implantation. Hydrogels suffer from low modulus, low yield stress and low strength when compared to non-swollen polymer systems. Lower mechanical properties result from the swollen nature of hydrogels and the non-stress bearing nature of the swelling agent, e.g., aqueous fluids. [0008]
[0009] Accordingly, there is a need in the art to provide shaped medical devices which not only offer the advantages of polymer hydrogels in terms of biological compatibility, but which also have improved mechanical properties, e.g. improved strength and modulus properties, such that they retain their shape and stiffness during insertion into the body, such as by delivery through an endoscope, and which also can swell and soften inside the body to enhance patient comfort. [0009] SUMMARY OF THE INVENTION
[0010] This invention provides a means of boosting the mechanical performance of shaped medical devices comprising polymer hydrogels, such as stents, so that they may be more easily inserted into the body, and at the same time provides a means to soften such devices in-vivo while retaining the structural integrity of the device. [0010]
[0011] The invention provides a process for improving the mechanical properties and structural integrity of a shaped medical device comprising a crosslinked polymeric hydrogel, said process comprising subjecting an ionically crosslinkable polymer composition to crosslinking conditions such that both ionic and non-ionic crosslinks are formed resulting in a polymeric hydrogel, wherein a medical device of improved structural integrity is obtained upon selective removal of said crosslinking ions from said polymeric hydrogel. [0011]
[0012] In addition, the invention also provides a process for improving the mechanical properties and structural integrity of a shaped medical device comprising a polymeric hydrogel, said process comprising: [0012]
[0013] a) providing a crosslinked polymeric hydrogel composition containing a non-ionic crosslink structure, said hydrogel polymer characterized as being ionically crosslinkable and having a primary shape; [0013]
[0014] b) imparting a secondary shape to said hydrogel polymer composition; and [0014]
[0015] c) subjecting said hydrogel polymer to ionic crosslinking conditions to tonically crosslink said hydrogel polymer while retaining said secondary shape. [0015]
[0016] A medical device substantially conforming to the primary shape of said hydrogel is obtained upon selective removal of the crosslinking ions from said crosslinked polymeric hydrogel, such as by removal of said ions after the device is implanted into the body. [0016]
[0017] The invention also provides a shaped medical device having improved mechanical properties comprising a cross-linked polymeric hydrogel, said hydrogel containing both an ionic and a non-ionic crosslink structure. The device is characterized by improved structural integrity after selective removal of said ionic crosslinking ions as compared with an otherwise identical device containing only an ionic structure. [0017]
[0018] The invention further provides a medical procedure comprising insertion of the above-described medical device into a human or animal body to form an implant, followed by the selective removal of at least a portion of the crosslinking ions from the implant in-vivo to soften the implant. Where the implant is later surgically removed, it may be once again subjected to ionic crosslinking conditions to ionically re-crosslink the implant prior to removal from the body. [0018] DETAILED DESCRIPTION OF THE INVENTION
[0019] The ionically crosslinkable polymers from which the medical devices of this invention may be fabricated may be anionic or cationic in nature and include but are not limited to carboxylic, sulfate, hydroxy and amine functionalized polymers, normally referred to as hydrogels after being crosslinked. The term “hydrogel” indicates a crosslinked, water insoluble, water containing material. [0019]
[0020] Suitable crosslinkable polymers which may be used in the present invention include but are not limited to one or a mixture of polymers selected from the group consisting of polyhydroxy ethyl methacrylate, polyvinyl alcohol, polyacrylamide, poly (N-vinyl pyrolidone), polyethylene oxide, hydrolysed polyacrylonitrile, polyacrylic acid, polymethacrylic acid, polyethylene amine, alginic acid, pectinic acid, carboxy methyl cellulose, hyaluronic acid, heparin, heparin sulfate, chitosan, carboxymethyl chitosan, chitin, pullulan, gellan, xanthan, carboxymethyl starch, carboxymethyl dextran, chondroitin sulfate, cationic guar, cationic starch as well as salts and esters thereof. Polymers listed above which are not ionically crosslinkable are used in blends with polymers which are ionically crosslinkable. [0020]
[0021] The most preferred polymers include one or a mixture of alginic acid, pectinic acid, carboxymethyl cellulose, hyaluronic acid, chitosan, polyvinyl alcohol and salts and esters thereof. Preferred anionic polymers are alginic or pectinic acid; preferred cationic polymers include chitosan, cationic guar, cationic starch and polyethylene amine. [0021]
[0022] Other preferred polymers include esters of alginic, pectinic or hyaluronic acid and C[0022] ₂to C₄polyalkylene glycols, e.g. propylene glycol, as well as blends containing 1 to 99 wt % of alginic,-pectinic or hyaluronic acid with 99 to 1 wt % polyacrylic acid, polymethacrylic acid or polyvinylalcohol. Preferred blends comprise alginic acid and polyvinylalcohol.
[0023] The crosslinking ions used to crosslink the polymers may be anions or cations depending on whether the polymer is anionically or cationically crosslinkable. Appropriate crosslinking ions include but are not limited to cations selected from the group consisting of calcium, magnesium, barium, strontium, boron, beryllium, aluminum, iron, copper, cobalt, lead and silver ions. Anions may be selected from but are not limited to the group consisting of phosphate, citrate, borate, succinate, maleate, adipate and oxalate ions. More broadly, the anions are derived from polybasic organic or inorganic acids. Preferred crosslinking cations are calcium, iron, and barium ions. The most preferred crosslinking cations are calcium and barium ions. The most preferred crosslinking anion is phosphate. Crosslinking may be carried out by contacting the polymers with an aqueous solution containing dissolved ions. [0023]
[0024] As indicated above, the polymer hydrogels forming the shaped medical device of this invention are also crosslinked by non-ionic crosslinking mechanisms to produce a device having a higher crosslink density and one which has improved mechanical properties, i.e., improved stiffness, modulus, yield stress and strength. This may be accomplished by additionally subjecting the tonically crosslinkable polymer to non-ionic crosslinking mechanisms such as high energy radiation (gamma rays) or treatment with a chemical crosslinking agent reactive with groups present in the polymer such that covalent bonds are formed connecting the polymer network. Another non-ionic crosslinking mechanism useful with respect to some classes of hydrogel polymers is physical crosslinking which is typically accomplished by crystal formation or similar association of polymer blocks such that the polymer molecules are physically tied together and prevented from complete dissolution. Non-ionic crosslinking may be carried out prior to, subsequent to or concurrently with ionic crosslinking. [0024]
[0025] The most preferred method for non-ionic crosslinking is contact of the tonically crosslinkable polymer with a chemical crosslinking agent, because the degree of crosslinking can be more readily controlled, mainly as a function of the concentration of the crosslinking agent in the reaction medium. Suitable crosslinking agents are polyfunctional compounds preferably having at least two functional groups reactive with one or more functional groups present in the polymer. Preferably the crosslinking agent contains one or more of carboxyl, hydroxy, epoxy, halogen or amino functional groups which are capable of undergoing facile nucleophilic or condensation reactions at temperatures up to about 100° C. with groups present along the polymer backbone or in the polymer structure. Suitable crosslinking reagents include polycarboxylic acids or anhydrides; polyamines; epihalohydrins; diepoxides; dialdehydes; diols; carboxylic acid halides, ketenes and like compounds. A particularly preferred crosslinking agent is glutaraldehyde. [0025]
[0026] One of the unique properties of the polymer hydrogels of this invention is that the ionic crosslinks can be easily and selectively displaced in-vivo after implantation of the device in the body, resulting in a swelling and softening of the device in the body which enhances patient comfort. Since the non-ionic crosslinks are not significantly displaced, the device will retain its original non-ionically crosslinked shape configuration to a large degree and will not disintegrate. [0026]
[0027] For example, a biliary or urethral stent can be fabricated which has improved modulus (stiffness) properties due to the dual crosslinking treatment of this invention. Such a stent will be robust enough and be sufficiently resistant to buckling such that it can be readily inserted into the appropriate part of the body with an endoscope. Once inserted, the ionic crosslinks present in the device can be selectively at least partially stripped either directly by the physician, by dietary means or by means of natural body fluids such as bile or urine. As the ionic crosslinks are removed, the modulus of the device will be lowered and the device will soften and swell in body fluids, resulting in a more comfortable and conformable element and a larger lumen through which body fluids-may flow. An enlarged lumen is typically preferred in tubular shaped devices to allow higher flow rates, to provide anchoring force to the body and to decrease the likelihood of occlusion during service. [0027]
[0028] Displacement of the crosslinking ions can be accomplished by flowing a solution containing a stripping agent around and/or through the medical device in-vivo. The stripping agent serves to displace, sequester or bind the crosslinking ions present in the ionically crosslinked polymer, thereby removing the ionic crosslinks. The choice of any particular stripping agent will depend on whether the ion to be displaced is an anion or a cation. Suitable stripping agents include but are not limited to organic acids and their salts or esters, phosphoric acid and salts or esters thereof, sulfate salts and alkali metal or ammonium salts. [0028]
[0029] Examples of stripping agents include, but are not limited to, ethylene diamine tetraacetic acid, ethylene diamine tetraacetate, citric acid and its salts, organic phosphates such as cellulose phosphate, inorganic phosphates, as for example, pentasodium tripolyphosphate, mono and dibasic potassium phosphate, sodium pyrophosphate, phosphoric acid, trisodium carboxymethyloxysuccinate, nitrilotriacetic acid, maleic acid, oxalate, polyacrylic acid, as well as sodium, potassium, lithium, calcium and magnesium ions. Preferred agents are citrate, inorganic phosphates and sodium, potassium and magnesium ions. The most preferred agents are inorganic phosphates and magnesium ions. [0029]
[0030] Specific methods for introduction of the stripping agent include introduction through the diet of the patient or through parenteral feeding, introduction of a solution directly onto the device such as by insertion of a catheter-which injects the. agent within the device, or through an enema. [0030]
[0031] For example, one dietary technique for stripping urinary device such as an implanted calcium alginate ureteral stent strippable by phosphate anions would be to include in the patient's diet materials which bind phosphate e.g., calcium salts, to lower the content of PO[0031] ₄ ⁻³present in the urine which can be normally up to about 0.1%. When it is desired to strip the medical device, phosphate binders can be eliminated from the diet and also replaced by foods or substances which generate phosphate ions in the urine. Achievement of levels of phosphate in the urine of from 0.2 to 0.3% will result in the in-vivo stripping of the calcium ions from the calcium alginate stent. Lower levels of phosphate in the urine will also result in a more gradual stripping of the calcium ions, but higher levels are preferred for rapid stripping of the calcium.
[0032] Another advantage of the invention is that the stripping process may be reversed to re-stiffen the medical device which facilitates surgical removal of the device from the body. This may be accomplished by flowing a source of crosslinking ions through and/or around the implant to ionically re-crosslink the implant, essentially the reverse of the stripping process described above. Dietary modifications can also be used to re-crosslink the medical device in-vivo. [0032]
[0033] In another embodiment of the invention, a secondary shape can be imparted to the medical device prior to implant in the body. This is accomplished by deforming the primary shape of a device which is crosslinked at least non-ionically, setting the device in the deformed shape by ionic crosslinking and implanting the device in the body in the deformed shape. Stripping the ions in-vivo as described above will cause the device to revert in-vivo to its primary non-ionically crosslinked shape. In accordance with one aspect of this embodiment, an tonically crosslinkable polymer is formed into a primary shape and subjected to non-ionic crosslinking conditions to form a non-ionically crosslinked hydrogel having said primary shape. Non-ionic crosslinking can be carried out by the methods described above, and is preferably carried out by extruding the polymer into a bath containing a sufficient amount of one or more of the non-ionic crosslinking agents to-form a shape-retaining hydrogel. Next, a secondary shape is imparted to the non-ionically crosslinked hydrogel and the hydrogel is then subjected to ionic crosslinking conditions to ionically crosslink the hydrogel while retaining this secondary shape. [0033]
[0034] In another aspect of this embodiment, an ionically crosslinkable polymer is formed into a primary shape and subjected to both non-ionic and ionic crosslinking conditions to form a hydrogel having said primary shape and containing both an ionic and non-ionic crosslink structure. In accordance with this second aspect, an ionically and non-ionically crosslinked shaped hydrogel is prepared as above. Then, the shaped hydrogel is selectively stripped ex-vivo of at least a portion or essentially all of the crosslinking ions; the shaped hydrogel is conformed to a secondary shape, e.g., bent around a wire, stretched, compressed or the like; and the shaped hydrogel is ionically re-crosslinked while retained in the secondary shape. Release of the crosslinking ions in-vivo will cause the implanted device to revert substantially to the original primary, non-ionically crosslinked shape. The stripping step described above can occur immediately prior to or subsequent to the secondary shaping step, but preferably subsequent such step but prior to the ionic recrosslink step. [0034]
[0035] This embodiment is particularly useful where the medical device is of hollow, tubular configuration, such as a stent. Where the stent is both ionically and non-ionically crosslinked, it is selectively stripped of the crosslinking ions. The stent is stretched to form a narrower stent which facilitates insertion into the body, ionically crosslinked or re-crosslinked in the stretched state to fix the stent in the stretched state, implanted in the body and then re-stripped in-vivo of the ionic crosslinks to produce a softer implant having a wider lumen. Other stent shapes such as pigtail ends, flaps, curves and the like can be developed in-vivo by subjecting devices having these primary initial shapes to the process described above, i.e., deforming the primary shape ex-vivo and reforming the primary shape in-vivo. [0035]
[0036] The stripping step described above is preferably accomplished by dipping or spraying the crosslinked device with an aqueous electrolyte solution for an appropriate time to selectively strip the crosslinking ions from the device. Preferred electrolytes for ex-vivo stripping are chlorides of monovalent cations such as sodium, potassium or lithium chloride, as well as other stripping salts described above. The concentration of the electrolyte salt in the solution may range from about 1 wt % up to the solubility limit. The solution may also contain plasticizing ingredients such as glycerol or sorbitol to facilitate inter and intra polymer chain motion during and after secondary shaping. [0036]
[0037] Secondary shaping of the medical device may be done by hand, i.e., using pinning boards or jig pins, or by using shaped presses or molds. [0037]
[0038] The device may be ionically crosslinked or re-crosslinked in the secondary shape by contacting the device, while retaining the secondary shape, with an aqueous solution containing the crosslinking ions described above. After crosslinking, the device will essentially retain the secondary shape. [0038]
[0039] Medical devices which may be fabricated in accordance with this invention include stents, catheters or cannulas, plugs and constrictors, for both human and animal use. The invention is particularly applicable to medical stents of tubular configuration which come in contact with one or more body fluids such as blood, urine, gastrointestinal fluids and bile. The devices are particularly applicable for use in gastrointestinal, urogenital, cardiovascular, lymphatic, otorhinolaryngological, optical, neurological, integument and muscular body systems. [0039]
[0040] The devices may optionally include fillers, disintegration agents, additives for medical treatment such as antiseptics, antibiotics, anticoagulants, or medicines, and additives for mechanical property adjustment of the device. [0040]
[0041] Linear device or pre-device -configurations -such as fibers, rods, tubes or ribbons can be manufactured in accordance with the present invention by using a spinning device in which an aqueous solution of an ionically crosslinkable matrix polymer is forced through a shaping die into a crosslinking bath containing the crosslinking ions. The product after crosslinking is typically described as a hydrogel. The hydrogel may be used as made, or further given a three dimensional shape through treatment in a crosslinking solution after being forced into the desired shape. After equilibration, the hydrogel will retain the new three dimension shape. The device may be used in its hydrogel form or in a dehydrated form. During dehydration, the three dimensional shape is retained. [0041]
[0042] Another process for manufacturing the articles of the present invention comprises introducing a solution comprising ionically crosslinkable polymer through a die to form a tube, simultaneously pumping a solution comprising crosslinking ion through the formed tube, and extruding the formed tube from said die into a solution comprising crosslinking ion. In this process, the crosslinking step may involve shaping of the device as in wet spinning of a tubular device. Alternatively, the device may be prepared by molding a latent crosslinking composition using a one or two part reaction injection molding system. The term “tubular” as used herein, includes not only cylindrical shaped devices having circular cross sections, but also devices having different cross sections as long as such articles have a hollow passageway, which distinguishes a tube from a rod. [0042]
[0043] The ionically crosslinked, shaped polymer prepared as above is then subjected to non-ionic crosslinking, e.g. high energy radiation or by contact under appropriate acidic or basic conditions with the appropriate chemical crosslinking agent. Crosslinking is preferably carried out by soaking the polymer in an aqueous solution containing a water soluble crosslinking agent such as glutaraldehyde, ethylene diamine or a lower alkylene glycol. Generally, the concentration of crosslinking agent in solution may range from about 0.25 to about 10 wt %, more preferably from about 0.5 to 5.0 wt %. The degree of non-ionic crosslinking is controlled as a function of the concentration of the crosslinking agent in solution. The level should be selected such that a stiffer, higher modulus device is produced which will revert to a soft, stretchy, shape retaining device after removal of the ionic crosslinks. Some trial and error may be required to determine optimum levels depending on the particular polymer and the identity of the crosslinking agent. [0043]
[0044] The crosslinking process may also be conducted by first crosslinking the polymer non-ionically, followed by ionic crosslinking, essentially the reverse of the process described above. [0044]
[0045] Where the ionically crosslinkable polymer composition includes polymers which are partially water soluble, it is preferred to include in the aqueous spinning solution and treatment solutions described above one or more additives which retard the tendency of the solution to dissolve the polymer, i.e., provide non-solvent conditions. Example of such conditions include high salt concentrations, or inclusion in the solution of additives such as borax, boric acid, alkali metal salts and/or a lower alcohol such as methanol. [0045]
[0046] The various steps may be performed at any suitable temperature, e.g., at room temperature or at temperatures up to about 100° C. Preferably, soaking steps are conducted at room temperature. Moreover, the steps may be performed one immediately after another, or a drying step (e.g., air-drying) may be interposed between one or more steps. Additionally, the shaped medical device may be sterilized after the sequence of secondary-shaping steps. [0046]
[0047] The medical device may be stored wet or dry. For example, the medical device may be stored in a suitable aqueous solution or may be dried prior to storage. For example, the medical device could be stored in deionized water, or in water containing water soluble agents such as glycerol, sorbitol, sucrose and the like. [0047]
[0048] Exemplary hydrogel systems which may be prepared in accordance with this invention can be prepared by the following procedures: [0048]
[0049] a) Alginate which has been covalently and ionically crosslinked. [0049]
[0050] A solution of sodium alginate is extruded through a tube die into a calcium chloride bath while calcium chloride solution is simultaneously introduced through the lumen of the tube. This ionically crosslinked tube is then covalently crosslinked by treatment with an aqueous solution containing glutaraldehyde. The now covalently and tonically crosslinked gel has a higher crosslink density and therefore higher modulus than a similar tube having only the covalent or only the ionic crosslinks. The tube therefore has higher stiffness and improved resistance to buckling than a tube having the covalent or ionic crosslinks alone. After insertion into the body, exposure of the tube to ions in body fluids will remove the calcium crosslinks, lower the modulus of the gel and therefore reduce the stiffness of the tube, allowing for maximum patient comfort and biocompatibility. Suitable ions which will displace the calcium crosslinking ions include phosphate, sulfate, carbonate, potassium, sodium and ammonium. The implanted device may be stiffened and strengthened during removal from the body via exposure of the device to an infusion fluid which contains a solution of the crosslinking ions (calcium). [0050]
[0051] b) Polyvinyl alcohol and alginate. [0051]
[0052] A blend of polyvinyl alcohol (PVA) and sodium alginate may be dispersed or dissolved in water, extruded into a bath containing calcium ions, said bath also containing non-solvent conditions for the polyvinyl alcohol. The polyvinyl alcohol component of the formed article may then be covalently crosslinked with an aqueous solution containing glutaraldehyde. The article is now ready for insertion or implantation. After implantation, the article may be softened and swollen by removal of the ionic crosslinks as above. Removal of the ionic crosslinks may also optionally allow the alginate to fully or partially dissolve in the body fluids, leaving behind a less dense, more porous hydrogel. The morphology of the final hydrogel device may be controlled through judicious selection of polyvinyl alcohol molecular weight, degree of crosslinking, solvent composition, alginate molecular weight, alginate salt used, state of the alginate salt (dissolved, particulated, gel), alginate monomer makeup, temperature, pressure, mix time, solution age, and rheological factors during manufacture. [0052]
[0053] c) Polyvinyl alcohol and alginate—shape memory. [0053]
[0054] The blend of PVA and sodium alginate described in (b) above may be used to make a stent having a shape memory feature to gain increased lumen size after deployment in-vivo. A tube is made by extruding the mixture through a tube die into a concentrated calcium chloride bath, optionally containing other salts and boric acid. The tube is then transferred into a bath which contains calcium chloride and a chemical crosslinker (glutaraldehyde). After allowing for reaction, the tube will become a covalently crosslinked PVA/calcium alginate system. The tube is immersed in concentrated potassium chloride solution to remove the calcium crosslinks from the alginate while preventing the alginate from dissolving. The tube is then stretched to form a longer length tube having a more narrow lumen. While in this stretched configuration, the tube is immersed into concentrated calcium chloride solution to re-crosslink the alginate. The tube is frozen into the longer length, narrow lumen configuration. Upon insertion into the body, the tube will return to it's original shorter length, large lumen configuration as the calcium is stripped from the alginate. The alginate may eventually dissolve, leaving behind a more porous glutaraldehyde crosslinked PVA tube. Other imposed shapes may be used to accommodate body insertion in a compact form, followed by shape change upon displacement of the ionic crosslinks. [0054]
[0055] d) Propyleneglycol alginate. [0055]
[0056] Propyleneglycol alginate may be covalently crosslinked with ethylene diamine under basic conditions and ionically crosslinked with calcium ions. This covalently and tonically crosslinked material will exhibit higher stiffness than the material crosslinked with covalent linkages only. Removal of the ionic crosslinks will occur in-vivo after deployment in body fluid. A stent, catheter or cannula can be manufactured from this material, implanted while both ionically and covalently crosslinked, then in-vivo the device will soften as the ionic crosslinks are displaced. A device of this construction would provide stiffness for implantation and softness for patient comfort. [0056] EXAMPLE 1
[0057] This example illustrates the preparation of tubing from a mixture of sodium alginate (Protanol LF 10/60 from Pronova Bipolymers A. S., Drammen, Norway) and polyvinylalcohol (PVA). A series of four different formulations were prepared as shown in Table 1. [0057] TABLE 1 PVA/alginate (wt. rat.) 15/5 20/5 15/7.5 20/5 Deionized water 72 g 67.5 g 69.7 g 74.25 g PVA 13.5 g 18.0 g 13.5 g 19.8 g Sodium alginate 4.5 g 4.5 g 6.75 g 4.95 g Bismuth subcarbonate 9.68 g 9.77 g 9.69 g 9.9 g
[0058] The deionized water was weighed into a 4 oz. jar, while stirring the water, the PVA and sodium alginate were added and mixed until uniform. The jar was capped and heated to 100° C. to dissolve the ingredients. The jar was cooled to 37° C., then the bismuth. subcarbonate (radiopaque filler) which had been sifted through a 325 mesh screen was added and the composition was mixed with a jiffy mixer until uniform. The samples were loaded into 30 cc syringes, centrifuged to remove air, then extruded through a tubing die into a coagulant solution. The coagulant solution was made from 100 grams of calcium chloride dihydrate, 30 grams of sodium chloride, 50 grams of boric acid and 820 grams of deionized water. The spun tubing was left in the coagulant solution overnight. Lengths of tubing were then soaked in a glutaraldehyde/coagulant solution mixture to covalently crosslink the sample. Glutaraldehyde levels were tested from 0.5% by weight to 12.5% by weight. pH was adjusted to 1.5 using 20% HCL solution. After reacting overnight at room temperature, the tubes were examined and then immersed in 0.4% sodium phosphate solution to strip the ionic crosslinks. Results are recorded in Table 2. [0058] TABLE 2 Glutaraldehyde (wt %) 0.5% 1.0% 5.0% 12.5% 15/5 (PVA/Alginate soft, slightly stiffer, stiff, wt. ratio) stretchy stiffer but still brittle soft 15/7.5 (PVA/Alginate soft, slightly much stiff, wt. ratio) stretchy stiffer stiffer brittle 20/5 (PVA/Alginate soft, slightly stiff, stiff, wt. ratio) stretchy stiffer brittle brittle
[0059] Control samples which were not treated with glutaraldehyde were swollen and broken apart in the phosphate solution. [0059]

权利要求:
Claims (64)
[1" id="US-20010002411-A1-CLM-00001] 1. A process for improving the mechanical properties and structural integrity of a shaped medical device comprising a crosslinked polymeric hydrogel, said process comprising subjecting an ionically crosslinkable polymer composition to crosslinking conditions such that both ionic and non-ionic crosslinks are formed resulting in a polymeric hydrogel.
[2" id="US-20010002411-A1-CLM-00002] 2. The process of
claim 1 wherein said ionic crosslinks are formed by contacting said ionically crosslinkable polymer with a source of ions.
[3" id="US-20010002411-A1-CLM-00003] 3. The process of
claim 2 wherein said polymer comprises one or a mixture of polymers selected from the group consisting of polyhydroxy ethyl methacrylate, polyvinyl alcohol, polyacrylamide, poly (N-vinyl pyrolidone), polyethylene oxide, hydrolysed polyacrylonitrile, polyacrylic acid, polymethacrylic acid, polyethylene amine, alginic acid, pectinic acid, carboxy methyl cellulose, hyaluronic acid, heparin, heparin sulfate, chitosan, carboxymethyl chitosan, chitin, pullulan, gellan, xanthan, carboxymethyl starch, carboxymethyl dextran, chondroitin sulfate, cationic guar, cationic starch as well as salts and esters thereof.
[4" id="US-20010002411-A1-CLM-00004] 4. The process of
claim 2 wherein said polymer comprises an anionic polymer and said ions are cations selected from the group consisting of calcium, magnesium, barium, strontium, boron, beryllium, aluminum, iron, copper, lead and silver ions.
[5" id="US-20010002411-A1-CLM-00005] 5. The process of
claim 2 wherein said polymer comprises a cationic polymer and said ions are anions selected from the group consisting of phosphate, citrate, borate, succinate, maleate, adipate and oxalate ions.
[6" id="US-20010002411-A1-CLM-00006] 6. The process of
claim 2 wherein said polymer comprises one or a mixture of cationic polymers selected from the group consisting of chitosan, cationic guar, cationic starch and polyethylene amine.
[7" id="US-20010002411-A1-CLM-00007] 7. The process of
claim 1 wherein said non-ionic crosslinks are formed by contacting said ionically crosslinkable polymer under reaction conditions with a crosslinking agent having at least two functional groups reactive with one or more functional groups present in said hydrogel polymer to form covalent bonds.
[8" id="US-20010002411-A1-CLM-00008] 8. The process of
claim 7 wherein said crosslinking agent contains carboxyl, hydroxy, epoxy, halogen or amino functional groups.
[9" id="US-20010002411-A1-CLM-00009] 9. The process of
claim 8 wherein said crosslinking agent is selected from the group consisting of glutaraldehyde, epichlorohydrin, dianhydrides and diamines.
[10" id="US-20010002411-A1-CLM-00010] 10. The process of
claim 9 wherein said crosslinking agent is glutaraldehyde.
[11" id="US-20010002411-A1-CLM-00011] 11. The process of
claim 2 wherein said polymer comprises a polymer selected from the group consisting of one or a mixture of alginic acid, pectinic acid, carboxymethyl cellulose, hyaluronic acid, chitosan, polyvinylalcohol, and salts and esters thereof.
[12" id="US-20010002411-A1-CLM-00012] 12. The process of
claim 11 wherein said polymer comprises alginic acid.
[13" id="US-20010002411-A1-CLM-00013] 13. The process of
claim 11 wherein said polymer is an ester of alginic acid and a C₂to C₄alkylene glycol.
[14" id="US-20010002411-A1-CLM-00014] 14. The process of
claim 13 wherein said alkylene glycol is propylene glycol.
[15" id="US-20010002411-A1-CLM-00015] 15. The process of
claim 2 wherein said polymer comprises a mixture of alginic or pectinic acid and polyvinylalcohol.
[16" id="US-20010002411-A1-CLM-00016] 16. The process of
claim 1 wherein said shaped medical device is in the form of a cylindrical hollow tube.
[17" id="US-20010002411-A1-CLM-00017] 17. The process of
claim 1 wherein said shaped medical device is selected from the group consisting of stents, catheters or cannulas, plugs, constrictors and tissue or biological encapsulants.
[18" id="US-20010002411-A1-CLM-00018] 18. A process for improving the mechanical properties and structural integrity of a shaped medical device comprising a polymeric hydrogel, said process comprising:
a) providing a crosslinked polymeric hydrogel composition containing a non-ionic crosslink structure, said hydrogel polymer characterized as being ionically crosslinkable and having a primary shape;
b) imparting a secondary shape to said hydrogel polymer composition; and
c) subjecting said hydrogel polymer to ionic crosslinking conditions to ionically crosslink said hydrogel polymer while retaining said secondary shape.
[19" id="US-20010002411-A1-CLM-00019] 19. The process of
claim 18 wherein said crosslinked polymeric hydrogel contains both an ionic and non-ionic crosslink structure, and wherein at least a portion of the crosslinking ions are selectively stripped away either prior to or subsequent to step (b) but prior to step (c).
[20" id="US-20010002411-A1-CLM-00020] 20. The process of
claim 19 wherein said crosslinking ions are selectively stripped away subsequent to step (b).
[21" id="US-20010002411-A1-CLM-00021] 21. The process of
claim 19 wherein said crosslinking ions are selectively stripped away by contacting said crosslinked hydrogel polymer with an aqueous electrolytic solution containing monovalent cations.
[22" id="US-20010002411-A1-CLM-00022] 22. The process of
claim 21 wherein said monovalent cations are selected from the group consisting of potassium, sodium and lithium.
[23" id="US-20010002411-A1-CLM-00023] 23. The process of
claim 18 wherein said non-ionic crosslink structure present in said crosslinked polymeric hydrogel is formed by contact of said polymer under reaction conditions with a crosslinking agent having at least two functional groups reactive with one or more functional groups present in said polymer to form covalent bonds.
[24" id="US-20010002411-A1-CLM-00024] 24. The process of
claim 23 wherein said crosslinking agent contains carboxyl, hydroxy, epoxy, halogen or amino functional groups.
[25" id="US-20010002411-A1-CLM-00025] 25. The process of
claim 24 wherein said crosslinking agent is selected from the group consisting of glutaraldehyde, epichlorohydrin, dianhydrides and diamines.
[26" id="US-20010002411-A1-CLM-00026] 26. The process of
claim 25 wherein said crosslinking agent is glutaraldehyde.
[27" id="US-20010002411-A1-CLM-00027] 27. The process of
claim 18 wherein said step (c) is carried out by contacting said hydrogel polymer with an aqueous solution containing ions.
[28" id="US-20010002411-A1-CLM-00028] 28. The process of
claim 27 wherein said hydrogel polymer comprises an anionic polymer and said ions are cations selected from the group consisting of calcium, magnesium, barium, strontium, boron, beryllium, aluminum, iron, copper, lead and silver.
[29" id="US-20010002411-A1-CLM-00029] 29. The process of
claim 27 wherein said hydrogel polymer comprises a cationic polymer and said ions are anions selected from the group consisting of phosphate, citrate, borate, succinate, maleate, adipate and oxalate ions.
[30" id="US-20010002411-A1-CLM-00030] 30. The process of
claim 18 wherein said shaped medical device is selected from the group consisting of stents, catheters or cannulas, plugs, constrictors and tissue or biological encapsulants.
[31" id="US-20010002411-A1-CLM-00031] 31. A shaped medical device having improved mechanical properties comprising a crosslinked polymeric hydrogel, said hydrogel containing both an ionic and a non-ionic crosslink structure.
[32" id="US-20010002411-A1-CLM-00032] 32. The device of
claim 31 wherein said non-ionic crosslink structure is a covalent crosslink structure.
[33" id="US-20010002411-A1-CLM-00033] 33. The device of
claim 31 wherein, upon selective removal of the ionic crosslinks, said device reconfigures substantially to the non-ionically crosslinked shape.
[34" id="US-20010002411-A1-CLM-00034] 34. The device of
claim 31 wherein said hydrogel comprises one or a mixture of polymers selected from the group consisting of polyhydroxy ethyl methacrylate, polyvinyl alcohol, polyacrylamide, poly (N-vinyl pyrolidone), polyethylene oxide, hydrolysed polyacrylonitrile, polyacrylic acid, polymethacrylic acid, polyethylene amine, alginic acid, pectinic acid, carboxy methyl cellulose, hyaluronic acid, heparin, heparin sulfate, chitosan, carboxymethyl chitosan, chitin, pullulan, gellan, xanthan, carboxymethyl starch, carboxymethyl dextran, chondroitin sulfate, cationic guar, cationic starch as well as salts and esters thereof.
[35" id="US-20010002411-A1-CLM-00035] 35. The device of
claim 31 wherein said hydrogel comprises an anionic polymer and said ions are cations selected from the group consisting of calcium, magnesium, barium, strontium, boron, beryllium, aluminum, iron, copper, lead and silver ions.
[36" id="US-20010002411-A1-CLM-00036] 36. The device of
claim 31 wherein said hyrdrogel comprises a cationic polymer and said ions are anions selected from the group consisting of phosphate, citrate, borate, succinate, maleate, adipate and oxalate ions.
[37" id="US-20010002411-A1-CLM-00037] 37. The device of
claim 31 wherein said hydrogel comprises one or a mixture of cationic polymers selected from the group consisting of chitosan, cationic guar, cationic starch and polyethylene amine.
[38" id="US-20010002411-A1-CLM-00038] 38. The device of
claim 31 wherein said non-ionic crosslink structure is formed by contacting said tonically crosslinkable polymer under reaction conditions with a crosslinking agent having at least two functional groups reactive with one or more functional groups present in said hydrogel polymer to form covalent bonds.
[39" id="US-20010002411-A1-CLM-00039] 39. The device of
claim 38 wherein said crosslinking agent contains carboxyl, hydroxy, epoxy, halogen or amino functional groups.
[40" id="US-20010002411-A1-CLM-00040] 40. The device of
claim 39 wherein said crosslinking agent is selected from the group consisting of glutaraldehyde, epichlorohydrin, dianhydrides and diamines.
[41" id="US-20010002411-A1-CLM-00041] 41. The device of
claim 40 wherein said crosslinking agent is glutaraldehyde.
[42" id="US-20010002411-A1-CLM-00042] 42. The device of
claim 31 wherein said hydrogel comprises a polymer selected from the group consisting of one or a mixture of alginic acid, pectinic acid, carboxymethyl cellulose, hyaluronic acid, chitosan, polyvinylalcohol, and salts and esters thereof.
[43" id="US-20010002411-A1-CLM-00043] 43. The device of
claim 42 wherein said hydrogel comprises alginic acid.
[44" id="US-20010002411-A1-CLM-00044] 44. The device of
claim 42 wherein said hydrogel is an ester of alginic acid and a C₂to C₄alkylene glycol.
[45" id="US-20010002411-A1-CLM-00045] 45. The device of
claim 44 wherein said alkylene glycol is propylene glycol.
[46" id="US-20010002411-A1-CLM-00046] 46. The device of
claim 42 wherein said hydrogel comprises a mixture of alginic or pectinic acid and polyvinylalcohol.
[47" id="US-20010002411-A1-CLM-00047] 47. The device of
claim 31 in the shape of a cylindrical, hollow tube.
[48" id="US-20010002411-A1-CLM-00048] 48. The device of
claim 31 wherein said shaped medical device is selected from the group consisting of stents, catheters or cannulas, plugs, constrictors and tissue or biological encapsulants.
[49" id="US-20010002411-A1-CLM-00049] 49. A medical procedure comprising:
a. inserting the medical device of
claim 31 into a human or animal body to form an implant; and
b. selectively removing at least a portion of said crosslinking ions from said implant in-vivo to soften said implant.
[50" id="US-20010002411-A1-CLM-00050] 50. The procedure of
claim 49 further including the step:
c. subjecting said implant to ionic crosslinking conditions to ionically re-crosslink said implant prior to removal thereof from said body.
[51" id="US-20010002411-A1-CLM-00051] 51. The procedure of
claim 49 wherein said implant is a cylindrical hollow tube.
[52" id="US-20010002411-A1-CLM-00052] 52. The procedure of
claim 49 wherein said hydrogel comprises one or a mixture of polymers selected from the group consisting of polyhydroxy ethyl methacrylate, polyvinyl alcohol, polyacrylamide, poly (N-vinyl pyrolidone), polyethylene oxide, hydrolysed polyacrylonitrile, polyacrylic acid, polymethacrylic acid, polyethylene amine, alginic acid, pectinic acid, carboxy methyl cellulose, hyaluronic acid, heparin, heparin sulfate, chitosan, carboxymethyl chitosan, chitin, pullulan, gellan, xanthan, carboxymethyl starch, carboxymethyl dextran, chondroitin sulfate, cationic guar, cationic starch as well as salts and esters thereof.
[53" id="US-20010002411-A1-CLM-00053] 53. The procedure of
claim 49 wherein said hydrogel comprises an anionic polymer and said ions are cations selected from the group consisting of calcium, magnesium, barium, strontium, boron, beryllium, aluminum, iron, copper, lead and silver ions.
[54" id="US-20010002411-A1-CLM-00054] 54. The procedure of
claim 49 wherein said hydrogel comprises a cationic polymer and said ions are anions selected from the group consisting of phosphate, citrate, borate, succinate, maleate, adipate and oxalate ions.
[55" id="US-20010002411-A1-CLM-00055] 55. The procedure of
claim 49 wherein said hydrogel comprises one or a mixture of cationic polymers selected from the group consisting of chitosan, cationic guar, cationic starch and polyethylene amine.
[56" id="US-20010002411-A1-CLM-00056] 56. The procedure of
claim 49 wherein said non-ionic crosslink structure is formed by contacting said ionically crosslinkable polymer under reaction conditions with a crosslinking agent having at least two functional groups reactive with one or more functional groups present in said hydrogel polymer to form covalent bonds.
[57" id="US-20010002411-A1-CLM-00057] 57. The procedure of
claim 56 wherein said crosslinking agent contains carboxyl, hydroxy, epoxy, halogen or amino functional groups.
[58" id="US-20010002411-A1-CLM-00058] 58. The procedure of
claim 57 wherein said crosslinking agent is selected from the group consisting of glutaraldehyde, epichlorohydrin, dianhydrides and diamines.
[59" id="US-20010002411-A1-CLM-00059] 59. The procedure of
claim 58 wherein said crosslinking agent is glutaraldehyde.
[60" id="US-20010002411-A1-CLM-00060] 60. The procedure of
claim 49 wherein said hydrogel comprises a polymer selected from the group consisting of one or a mixture of alginic acid, pectinic acid, carboxymethyl cellulose, hyaluronic acid, chitosan, polyvinylalcohol, and salts and esters thereof.
[61" id="US-20010002411-A1-CLM-00061] 61. The procedure of
claim 60 wherein said hydrogel comprises alginic acid.
[62" id="US-20010002411-A1-CLM-00062] 62. The procedure of
claim 60 wherein said hydrogel is an ester of alginic acid and a C₂to C₄alkylene glycol.
[63" id="US-20010002411-A1-CLM-00063] 63. The procedure of
claim 62 wherein said alkylene glycol is propylene glycol.
[64" id="US-20010002411-A1-CLM-00064] 64. The procedure of
claim 60 wherein said hydrogel comprises a mixture of alginic or pectinic acid and polyvinylalcohol.

类似技术:

公开号 | 公开日 | 专利标题

US6387978B2|2002-05-14|Medical devices comprising ionically and non-ionically crosslinked polymer hydrogels having improved mechanical properties

US6368356B1|2002-04-09|Medical devices comprising hydrogel polymers having improved mechanical properties

US5650116A|1997-07-22|Method of making a medical device from ironically crosslinked polymer

JP4331795B2|2009-09-16|Medical device with improved elastic response

EP0912145B1|2005-09-14|Medical devices containing in-situ generated medical compounds

US5718862A|1998-02-17|Secondary shaping of ionically crosslinked polymer compositions for medical devices

JPH0899908A|1996-04-16|Medical device containing decay agent as trigger

EP0684045A1|1995-11-29|Crosslinked compositions with improved mechanical performance

WO2000050103A1|2000-08-31|Medical devices comprising hydrogel polymers having improved mechanical properties

CN110404083B|2021-03-09|Injectable hydrogel material and preparation method and application thereof

CA2252600C|2006-10-24|Secondary shaping of ionically cross-linked polymer compositions for medical devices

同族专利:

公开号 | 公开日

DE69725442D1|2003-11-13|

EP0912211B1|2003-10-08|

US6060534A|2000-05-09|

US6184266B1|2001-02-06|

EP0912211A4|2000-08-16|

CA2262523C|2005-09-20|

DE69725442T2|2004-07-29|

CA2262523A1|1998-01-22|

WO1998002204A1|1998-01-22|

EP0912211A1|1999-05-06|

US6387978B2|2002-05-14|

引用文献:

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

US20030044408A1|2001-06-15|2003-03-06|The Children's Hospital Of Philadelphia|Surface modification for improving biocompatibility|

US20030046545A1|2001-08-21|2003-03-06|Merkle James A.|Systems and methods for media authentication|

US20080071384A1|2006-09-19|2008-03-20|Travis Deal|Ureteral stent having variable hardness|

US20080132991A1|2006-11-30|2008-06-05|Leonard Pinchuk|Method for Ionically Cross-Linking Gellan Gum for Thin Film Applications and Medical Devices Produced Therefrom|

US20100234233A1|2007-08-10|2010-09-16|Alessandro Sannino|Polymer hydrogels and methods of preparation thereof|

WO2011066340A1|2009-11-24|2011-06-03|University Of Florida Research Foundation, Inc.|Apparatus and methods for blocking needle and cannula tracts|

US20110153030A1|2001-08-27|2011-06-23|Synecor, Llc|Positioning tools and methods for implanting medical devices|

WO2013159757A1|2012-04-25|2013-10-31|Contipro Biotech S.R.O.|Crosslinked hyaluronan derivative, method of preparation thereof, hydrogel and microfibers based thereon|

WO2017112878A1|2015-12-22|2017-06-29|Access Vascular, Inc.|High strength biomedical materials|

WO2020227705A1|2019-05-09|2020-11-12|Soliman Sherif|Hydrogel retinal tamponade agent|

US11130823B2|2011-06-07|2021-09-28|Gelesis Llc|Method for producing hydrogels|

US11130824B2|2015-01-29|2021-09-28|Gelesis Llc|Method for producing hydrogels coupling high elastic modulus and absorbance|US2485512A|1941-10-21|1949-10-18|Alginate Ind Ltd|Manufacture of transparent alginic films|

GB674755A|1949-08-04|1952-07-02|Courtaulds Ltd|Improvements in and relating to the production of artificial protein fibres|

US2689809A|1951-10-08|1954-09-21|Permachem Corp|Self-sterilizing article and its preparation|

US2712672A|1952-01-28|1955-07-12|Calcagno Luigi|Process for preparing proteic sponges|

US2791518A|1955-03-21|1957-05-07|Permachem Corp|Process for making a microbicidal article|

US2847713A|1955-05-13|1958-08-19|Weingand Richard|Process for producing synthetic sausage skins and other laminar structures from alginates|

US2897547A|1955-05-27|1959-08-04|Weingand Richard|Process for producing synthetic sausage casing from alginates or alginic acid|

US3271496A|1964-01-27|1966-09-06|Amicon Corp|Method of shaping polyelectrolyte polymer|

US3975350A|1972-08-02|1976-08-17|Princeton Polymer Laboratories, Incorporated|Hydrophilic or hydrogel carrier systems such as coatings, body implants and other articles|

US4137921A|1977-06-24|1979-02-06|Ethicon, Inc.|Addition copolymers of lactide and glycolide and method of preparation|

SE425372B|1977-07-18|1982-09-27|Ird Biomaterial Ab|SET TO HEPARINIZE AN ELECTRICALLY CHARGED SURFACE ON A MEDICAL ARTICLE INTENDED TO CONTACT WITH BLOOD AND MEDICINES TO PERFORM THE SET|

DE2824893C2|1978-06-07|1980-04-24|Willy Ruesch Gmbh & Co Kg, 7053 Kernen|Enteral treatment probe|

US4339295A|1978-12-20|1982-07-13|The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services|Hydrogel adhesives and sandwiches or laminates using microwave energy|

US4286341A|1979-04-16|1981-09-01|Iowa State University Research Foundation, Inc.|Vascular prosthesis and method of making the same|

FR2484246B1|1980-06-17|1984-10-05|Europ Propulsion||

JPS6259606B2|1980-07-02|1987-12-11|Toray Industries||

EP0065884B1|1981-05-27|1986-08-20|Unitika Ltd.|Urethral catheter capable of preventing urinary tract infection and process for producing the same|

US4499154A|1982-09-03|1985-02-12|Howard L. Podell|Dipped rubber article|

US4700704A|1982-10-01|1987-10-20|Ethicon, Inc.|Surgical articles of copolymers of glycolide and ε-caprolactone and methods of producing the same|

US4886870A|1984-05-21|1989-12-12|Massachusetts Institute Of Technology|Bioerodible articles useful as implants and prostheses having predictable degradation rates|

US4613517A|1983-04-27|1986-09-23|Becton, Dickinson And Company|Heparinization of plasma treated surfaces|

US4527293A|1983-05-18|1985-07-09|University Of Miami|Hydrogel surface of urological prosthesis|

US4592920A|1983-05-20|1986-06-03|Baxter Travenol Laboratories, Inc.|Method for the production of an antimicrobial catheter|

GB8318403D0|1983-07-07|1983-08-10|Sutherland I W|Gel-forming polysaccharides|

CA1238043A|1983-12-15|1988-06-14|Endre A. Balazs|Water insoluble preparations of hyaluronic acid andprocesses therefor|

FR2559666B1|1984-02-21|1986-08-08|Tech Cuir Centre|PROCESS FOR THE MANUFACTURE OF COLLAGEN TUBES, ESPECIALLY LOW-DIAMETER TUBES, AND APPLICATION OF THE TUBES OBTAINED IN THE FIELD OF VASCULAR PROSTHESES AND NERVOUS SUTURES|

US4716224A|1984-05-04|1987-12-29|Seikagaku Kogyo Co. Ltd.|Crosslinked hyaluronic acid and its use|

US4650488A|1984-05-16|1987-03-17|Richards Medical Company|Biodegradable prosthetic device|

SE442820B|1984-06-08|1986-02-03|Pharmacia Ab|GEL OF THE CROSS-BOND HYALURONIC ACID FOR USE AS A GLASS BODY SUBSTITUTE|

US4863907A|1984-06-29|1989-09-05|Seikagaku Kogyo Co., Ltd.|Crosslinked glycosaminoglycans and their use|

JPH0340266Y2|1984-07-28|1991-08-23|||

US4801475A|1984-08-23|1989-01-31|Gregory Halpern|Method of hydrophilic coating of plastics|

US4674506A|1984-11-29|1987-06-23|Kirk Alcond|Surgical anastomosis stent|

US5128326A|1984-12-06|1992-07-07|Biomatrix, Inc.|Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same|

US4582865A|1984-12-06|1986-04-15|Biomatrix, Inc.|Cross-linked gels of hyaluronic acid and products containing such gels|

US4605691A|1984-12-06|1986-08-12|Biomatrix, Inc.|Cross-linked gels of hyaluronic acid and products containing such gels|

US4636524A|1984-12-06|1987-01-13|Biomatrix, Inc.|Cross-linked gels of hyaluronic acid and products containing such gels|

US4871365A|1985-04-25|1989-10-03|American Cyanamid Company|Partially absorbable prosthetic tubular article having an external support|

US5202431A|1985-07-08|1993-04-13|Fidia, S.P.A.|Partial esters of hyaluronic acid|

US4851521A|1985-07-08|1989-07-25|Fidia, S.P.A.|Esters of hyaluronic acid|

AU589438B2|1985-08-26|1989-10-12|Hana Biologics, Inc.|Transplantable artificial tissue and process|

US4997443A|1985-08-26|1991-03-05|Hana Biologics, Inc.|Transplantable artificial tissue and process|

US4902295A|1985-08-26|1990-02-20|Hana Biologics, Inc.|Transplantable artificial tissue|

SE8504501D0|1985-09-30|1985-09-30|Astra Meditec Ab|METHOD OF FORMING AN IMPROVED HYDROPHILIC COATING ON A POLYMER SURFACE|

US5298569A|1985-10-30|1994-03-29|Nippon Paint Co.|Metallic ester acrylic compositions capable of releasing bioactive substance at a controlled rate|

US4838876A|1986-04-29|1989-06-13|The Kendall Company|Silicone rubber catheter having improved surface morphology|

FI81010C|1986-09-05|1990-09-10|Biocon Oy|Benomplaceringsimplants|

EP0261470B1|1986-09-23|1993-05-05|American Cyanamid Company|Bioabsorbable coating for a surgical article|

IT1198449B|1986-10-13|1988-12-21|F I D I Farmaceutici Italiani|ESTERS OF POLYVALENT ALCOHOLS OF HYALURONIC ACID|

GB8630363D0|1986-12-19|1987-01-28|Igel Int Ltd|Coloured hydrogel objects|

IL82834A|1987-06-09|1990-11-05|Yissum Res Dev Co|Biodegradable polymeric materials based on polyether glycols,processes for the preparation thereof and surgical artiicles made therefrom|

US5527337A|1987-06-25|1996-06-18|Duke University|Bioabsorbable stent and method of making the same|

US5059211A|1987-06-25|1991-10-22|Duke University|Absorbable vascular stent|

US4923645A|1987-11-16|1990-05-08|Damon Biotech, Inc.|Sustained release of encapsulated molecules|

US4916193A|1987-12-17|1990-04-10|Allied-Signal Inc.|Medical devices fabricated totally or in part from copolymers of recurring units derived from cyclic carbonates and lactides|

US4958038A|1987-12-21|1990-09-18|E. I. Du Pont De Nemours And Company|Organotitanium compositions useful for cross-linking|

JP2561853B2|1988-01-28|1996-12-11|株式会社ジェイ・エム・エス|Shaped memory molded article and method of using the same|

US5147399A|1988-02-01|1992-09-15|Dellon Arnold L|Method of treating nerve defects through use of a bioabsorbable surgical device|

US4888016A|1988-02-10|1989-12-19|Langerman David W|"Spare parts" for use in ophthalmic surgical procedures|

US5061738A|1988-04-18|1991-10-29|Becton, Dickinson And Company|Blood compatible, lubricious article and composition and method therefor|

IT1219587B|1988-05-13|1990-05-18|Fidia Farmaceutici|SELF-CROSS-LINKED CARBOXYLY POLYSACCHARIDES|

US4874360A|1988-07-01|1989-10-17|Medical Engineering Corporation|Ureteral stent system|

US5444113A|1988-08-08|1995-08-22|Ecopol, Llc|End use applications of biodegradable polymers|

US5502158A|1988-08-08|1996-03-26|Ecopol, Llc|Degradable polymer composition|

WO1990001969A1|1988-08-24|1990-03-08|Slepian Marvin J|Biodegradable polymeric endoluminal sealing|

US4938763B1|1988-10-03|1995-07-04|Atrix Lab Inc|Biodegradable in-situ forming implants and method of producing the same|

US5085629A|1988-10-06|1992-02-04|Medical Engineering Corporation|Biodegradable stent|

FI85223C|1988-11-10|1992-03-25|Biocon Oy|Biodegrading surgical implants and agents|

US5057606A|1989-01-24|1991-10-15|Minnesota Mining And Manufacturing Company|Form-in-place polysaccharide gels|

US5089606A|1989-01-24|1992-02-18|Minnesota Mining And Manufacturing Company|Water-insoluble polysaccharide hydrogel foam for medical applications|

US4948575A|1989-01-24|1990-08-14|Minnesota Mining And Manufacturing Company|Alginate hydrogel foam wound dressing|

US5554388A|1989-02-25|1996-09-10|Danbiosyst Uk Limited|Systemic drug delivery compositions comprising a polycationi substance|

US5425739A|1989-03-09|1995-06-20|Avatar Design And Development, Inc.|Anastomosis stent and stent selection system|

US5324519A|1989-07-24|1994-06-28|Atrix Laboratories, Inc.|Biodegradable polymer composition|

US5141516A|1989-07-26|1992-08-25|Detweiler Mark B|Dissolvable anastomosis stent and method for using the same|

US5049138A|1989-11-13|1991-09-17|Boston Scientific Corporation|Catheter with dissolvable tip|

US4994074A|1990-02-01|1991-02-19|Ethicon, Inc.|Copolymers of ε-caprolactone, glycolide and glycolic acid for suture coatings|

DK0441516T3|1990-02-08|1995-06-12|Howmedica|Inflatable catheter|

US5178234A|1990-03-15|1993-01-12|Tokyo Electric Co., Ltd.|Checkout apparatus|

US5077352A|1990-04-23|1991-12-31|C. R. Bard, Inc.|Flexible lubricious organic coatings|

EP0454373B1|1990-04-23|1995-08-23|Monsanto Company|Gellan gum fibers|

NO171069C|1990-05-29|1993-01-20|Protan Biopolymer As|COVALENT CIRCUIT, STRONGLY SWELLING ALKALIMETAL AND AMMONIUM ALGINATE GELS, AND PROCEDURES FOR PREPARING THEREOF|

IT1248666B|1990-05-30|1995-01-26|Fidia Spa|GEL IN THE FORM OF HIGHLY HYDRATED SELF-SUPPORTING FILMS, PROCESS FOR THEIR PREPARATION AND USE IN THE THERAPY OF INJURIES AND / OR SKIN PATHOLOGIES|

US5077033A|1990-08-07|1991-12-31|Mediventures Inc.|Ophthalmic drug delivery with thermo-irreversible gels of polxoxyalkylene polymer and ionic polysaccharide|

US5149543A|1990-10-05|1992-09-22|Massachusetts Institute Of Technology|Ionically cross-linked polymeric microcapsules|

JP2777279B2|1990-10-08|1998-07-16|工業技術院長|Wound dressing and method for producing the same|

US5160341A|1990-11-08|1992-11-03|Advanced Surgical Intervention, Inc.|Resorbable urethral stent and apparatus for its insertion|

US5162110A|1990-12-19|1992-11-10|Rhone-Poulenc Rorer Pharmaceuticals Inc.|Binding theophylline to ion exchange resins|

GR920100122A|1991-04-05|1993-03-16|Ethicon Inc|Ionically crosslinked carboxyl-containing polysaccharides for adhension prevention.|

BR9205879A|1991-04-10|1994-07-05|Christopher C Capelli|Antimicrobial composition, adhesive composition, mammalian infection treatment process and process for providing antimicrobial protection to a patient|

US5662913A|1991-04-10|1997-09-02|Capelli; Christopher C.|Antimicrobial compositions useful for medical applications|

US5302393A|1991-07-11|1994-04-12|Kanegafuchi Kagaku Kogyo Kabushiki Kaisha|Method for inhibiting biological degradation of implantation polymeric material, inhibitor thereof and implantation polymeric material containing the inhibitor|

EP0610441A4|1991-10-29|1996-01-10|Clover Cons Ltd|Crosslinkable polysaccharides, polycations and lipids useful for encapsulation and drug release.|

US5200195A|1991-12-06|1993-04-06|Alza Corporation|Process for improving dosage form delivery kinetics|

DK0625070T3|1991-12-20|1999-02-22|Allied Signal Inc|Low density materials having high surface area and articles formed therefrom for use in recycling|

US5489297A|1992-01-27|1996-02-06|Duran; Carlos M. G.|Bioprosthetic heart valve with absorbable stent|

KR100292923B1|1993-05-03|2001-06-15|브루노 케레스, 헬무트 클림멕|Polymer compositions, absorbent compositions, methods for their preparation and methods of use|

US5334640A|1992-04-08|1994-08-02|Clover Consolidated, Ltd.|Ionically covalently crosslinked and crosslinkable biocompatible encapsulation compositions and methods|

US5428123A|1992-04-24|1995-06-27|The Polymer Technology Group|Copolymers and non-porous, semi-permeable membrane thereof and its use for permeating molecules of predetermined molecular weight range|

US5306764A|1992-09-03|1994-04-26|China Technical Consultants Inc.|Water dispersible polyurethane and process for preparation thereof|

US5292525A|1992-10-14|1994-03-08|Merck & Co., Inc.|Method and composition for removing an alginate from a cutaneous substrate|

US5443458A|1992-12-22|1995-08-22|Advanced Cardiovascular Systems, Inc.|Multilayered biodegradable stent and method of manufacture|

US5401257A|1993-04-27|1995-03-28|Boston Scientific Corporation|Ureteral stents, drainage tubes and the like|

US5328939A|1993-04-27|1994-07-12|Alliedsignal Inc.|Rigid materials having high surface area and low density|

CA2123647C|1993-06-11|2007-04-17|Steven L. Bennett|Bioabsorbable copolymer and coating composition containing same|

US5425949A|1993-06-11|1995-06-20|United States Surgical Corporation|Bioabsorbable copolymer and coating composition containing same|

US5531716A|1993-09-29|1996-07-02|Hercules Incorporated|Medical devices subject to triggered disintegration|

US5514377A|1994-03-08|1996-05-07|The Regents Of The University Of California|In situ dissolution of alginate coatings of biological tissue transplants|

US5541304A|1994-05-02|1996-07-30|Hercules Incorporated|Crosslinked hydrogel compositions with improved mechanical performance|

US5629077A|1994-06-27|1997-05-13|Advanced Cardiovascular Systems, Inc.|Biodegradable mesh and film stent|

US5603955A|1994-07-18|1997-02-18|University Of Cincinnati|Enhanced loading of solutes into polymer gels|

US5578662A|1994-07-22|1996-11-26|United States Surgical Corporation|Bioabsorbable branched polymers containing units derived from dioxanone and medical/surgical devices manufactured therefrom|

US5527324A|1994-09-07|1996-06-18|Krantz; Kermit E.|Surgical stent|

US5531735A|1994-09-27|1996-07-02|Hercules Incorporated|Medical devices containing triggerable disintegration agents|

US5690961A|1994-12-22|1997-11-25|Hercules Incorporated|Acidic polysaccharides crosslinked with polycarboxylic acids and their uses|

WO1996025897A2|1995-02-22|1996-08-29|Menlo Care, Inc.|Covered expanding mesh stent|

US5713852A|1995-06-07|1998-02-03|Alza Corporation|Oral dosage and method for treating painful conditions of the oral cavity|

US5702682A|1995-12-01|1997-12-30|Hercules Incorporated|Methods for preparing radiopaque medical devices|

US5684051A|1996-04-24|1997-11-04|Hercules Incorporated|Medical devices with improved elastic response|

US5670161A|1996-05-28|1997-09-23|Healy; Kevin E.|Biodegradable stent|

US5820918A|1996-07-11|1998-10-13|Hercules Incorporated|Medical devices containing in-situ generated medical compounds|

US5830217A|1996-08-09|1998-11-03|Thomas J. Fogarty|Soluble fixation device and method for stent delivery catheters|

US5718916A|1997-02-03|1998-02-17|Scherr; George H.|Alginate foam products|US6214331B1|1995-06-06|2001-04-10|C. R. Bard, Inc.|Process for the preparation of aqueous dispersions of particles of water-soluble polymers and the particles obtained|

US6818018B1|1998-08-14|2004-11-16|Incept Llc|In situ polymerizable hydrogels|

US6211296B1|1998-11-05|2001-04-03|The B. F. Goodrich Company|Hydrogels containing substances|

US6348042B1|1999-02-02|2002-02-19|W. Lee Warren, Jr.|Bioactive shunt|

GB9902412D0†|1999-02-03|1999-03-24|Fermentech Med Ltd|Process|

GB9902652D0|1999-02-05|1999-03-31|Fermentech Med Ltd|Process|

AU3503700A|1999-02-25|2000-09-14|Scimed Life Systems, Inc.|Medical devices comprising hydrogel polymers having improved mechanical properties|

WO2002034304A1|2000-10-23|2002-05-02|Tissuemed Limited|Self-adhesive hydratable matrix for topical therapeutic use|

WO2001036000A1|1999-11-15|2001-05-25|Bio Syntech Canada, Inc.|Temperature-controlled and ph-dependant self-gelling biopolymeric aqueous solution|

DE60004710T2|1999-12-09|2004-07-08|Biosyntech Canada Inc., Laval|MINERAL-POLYMER HYBRID COMPOSITION|

US20030158302A1|1999-12-09|2003-08-21|Cyric Chaput|Mineral-polymer hybrid composition|

US6355058B1|1999-12-30|2002-03-12|Advanced Cardiovascular Systems, Inc.|Stent with radiopaque coating consisting of particles in a binder|

AU778318B2|2000-02-03|2004-11-25|Tissuemed Limited|Device for the closure of a surgical puncture|

AU2001245660B2|2000-03-13|2006-06-15|Biocompatibles Uk Limited|Embolic compositions|

US6652883B2|2000-03-13|2003-11-25|Biocure, Inc.|Tissue bulking and coating compositions|

WO2001068721A1|2000-03-13|2001-09-20|Biocure, Inc.|Tissue bulking and coating compositions|

AU6888201A|2000-06-29|2002-01-08|Biosyntech Canada Inc|Composition and method for the repair and regeneration of cartilage and other tissues|

US7226615B2|2000-11-07|2007-06-05|Cryolife, Inc.|Expandable foam-like biomaterials and methods|

CA2429168C|2000-11-15|2010-06-08|Bio Syntech Canada Inc.|Method for restoring a damaged or degenerated intervertebral disc|

US6664335B2|2000-11-30|2003-12-16|Cardiac Pacemakers, Inc.|Polyurethane elastomer article with “shape memory” and medical devices therefrom|

US6635082B1|2000-12-29|2003-10-21|Advanced Cardiovascular Systems Inc.|Radiopaque stent|

US6685626B2|2001-02-02|2004-02-03|Regeneration Technologies, Inc.|Compositions, devices, methods, and kits for induction of adhesions|

US6913765B2|2001-03-21|2005-07-05|Scimed Life Systems, Inc.|Controlling resorption of bioresorbable medical implant material|

WO2002089865A2|2001-05-04|2002-11-14|Concentric Medical|Coated combination vaso-occlusive device|

WO2002089679A1|2001-05-04|2002-11-14|Concentric Medical|Hydrogel vaso-occlusive device|

EP1392175A2|2001-05-04|2004-03-03|Concentric Medical|Hydrogel filament vaso-occlusive device|

US7201940B1|2001-06-12|2007-04-10|Advanced Cardiovascular Systems, Inc.|Method and apparatus for thermal spray processing of medical devices|

US8715312B2|2001-07-20|2014-05-06|Microvention, Inc.|Aneurysm treatment device and method of use|

US8252040B2|2001-07-20|2012-08-28|Microvention, Inc.|Aneurysm treatment device and method of use|

US7572288B2|2001-07-20|2009-08-11|Microvention, Inc.|Aneurysm treatment device and method of use|

US20030073961A1|2001-09-28|2003-04-17|Happ Dorrie M.|Medical device containing light-protected therapeutic agent and a method for fabricating thereof|

US20030093111A1|2001-10-26|2003-05-15|Concentric Medical|Device for vaso-occlusion and interventional therapy|

US6783721B2|2001-10-30|2004-08-31|Howmedica Osteonics Corp.|Method of making an ion treated hydrogel|

US20030100830A1|2001-11-27|2003-05-29|Sheng-Ping Zhong|Implantable or insertable medical devices visible under magnetic resonance imaging|

US20040143180A1|2001-11-27|2004-07-22|Sheng-Ping Zhong|Medical devices visible under magnetic resonance imaging|

US8133501B2|2002-02-08|2012-03-13|Boston Scientific Scimed, Inc.|Implantable or insertable medical devices for controlled drug delivery|

GB0210216D0|2002-05-03|2002-06-12|First Water Ltd|Ionically crosslinked alginate hydrogels, process for their manufacture and their use in medical devices|

US20030215395A1|2002-05-14|2003-11-20|Lei Yu|Controllably degradable polymeric biomolecule or drug carrier and method of synthesizing said carrier|

US7056523B1|2002-06-21|2006-06-06|Advanced Cardiovascular Systems, Inc.|Implantable medical devices incorporating chemically conjugated polymers and oligomers of L-arginine|

US7396539B1|2002-06-21|2008-07-08|Advanced Cardiovascular Systems, Inc.|Stent coatings with engineered drug release rate|

US7033602B1|2002-06-21|2006-04-25|Advanced Cardiovascular Systems, Inc.|Polycationic peptide coatings and methods of coating implantable medical devices|

US8506617B1|2002-06-21|2013-08-13|Advanced Cardiovascular Systems, Inc.|Micronized peptide coated stent|

US7217426B1|2002-06-21|2007-05-15|Advanced Cardiovascular Systems, Inc.|Coatings containing polycationic peptides for cardiovascular therapy|

US7794743B2|2002-06-21|2010-09-14|Advanced Cardiovascular Systems, Inc.|Polycationic peptide coatings and methods of making the same|

US8920826B2|2002-07-31|2014-12-30|Boston Scientific Scimed, Inc.|Medical imaging reference devices|

US8685427B2|2002-07-31|2014-04-01|Boston Scientific Scimed, Inc.|Controlled drug delivery|

US7598224B2|2002-08-20|2009-10-06|Biosurface Engineering Technologies, Inc.|Dual chain synthetic heparin-binding growth factor analogs|

US8227411B2|2002-08-20|2012-07-24|BioSurface Engineering Technologies, Incle|FGF growth factor analogs|

US20040063805A1|2002-09-19|2004-04-01|Pacetti Stephen D.|Coatings for implantable medical devices and methods for fabrication thereof|

US20050010275A1|2002-10-11|2005-01-13|Sahatjian Ronald A.|Implantable medical devices|

US7468210B1|2002-12-10|2008-12-23|Biosurface Engineering Technologies, Inc.|Cross-linked heparin coatings and methods|

US7094256B1|2002-12-16|2006-08-22|Advanced Cardiovascular Systems, Inc.|Coatings for implantable medical device containing polycationic peptides|

US20040115164A1|2002-12-17|2004-06-17|Pierce Ryan K.|Soft filament occlusive device delivery system|

EP1610752B1|2003-01-31|2013-01-02|Boston Scientific Limited|Localized drug delivery using drug-loaded nanocapsules and implantable device coated with the same|

US7241455B2|2003-04-08|2007-07-10|Boston Scientific Scimed, Inc.|Implantable or insertable medical devices containing radiation-crosslinked polymer for controlled delivery of a therapeutic agent|

CA2638788A1|2003-04-25|2004-11-11|Kos Life Sciences, Inc.|Formation of strong superporous hydrogels|

US8791171B2|2003-05-01|2014-07-29|Abbott Cardiovascular Systems Inc.|Biodegradable coatings for implantable medical devices|

US6923996B2|2003-05-06|2005-08-02|Scimed Life Systems, Inc.|Processes for producing polymer coatings for release of therapeutic agent|

US7364585B2|2003-08-11|2008-04-29|Boston Scientific Scimed, Inc.|Medical devices comprising drug-loaded capsules for localized drug delivery|

US20050074406A1|2003-10-03|2005-04-07|Scimed Life Systems, Inc.|Ultrasound coating for enhancing visualization of medical device in ultrasound images|

US20050107867A1|2003-11-17|2005-05-19|Taheri Syde A.|Temporary absorbable venous occlusive stent and superficial vein treatment method|

CA2549295C|2003-12-04|2016-05-03|University Of Utah Research Foundation|Modified macromolecules and methods of making and using thereof|

EP1786485A4|2004-02-06|2012-05-30|Georgia Tech Res Inst|Surface directed cellular attachment|

US7910124B2|2004-02-06|2011-03-22|Georgia Tech Research Corporation|Load bearing biocompatible device|

JP4895826B2|2004-02-20|2012-03-14|バイオサーフェスエンジニアリングテクノロジーズ，インク．|Bone morphogenetic protein-2 positive modulator|

WO2005082978A1|2004-02-23|2005-09-09|E.I. Dupont De Nemours And Company|Preparation of crosslinked polymers containing biomass derived materials|

US20050220882A1|2004-03-04|2005-10-06|Wilson Pritchard|Materials for medical implants and occlusive devices|

US8067073B2|2004-03-25|2011-11-29|Boston Scientific Scimed, Inc.|Thermoplastic medical device|

US7282165B2|2004-04-27|2007-10-16|Howmedica Osteonics Corp.|Wear resistant hydrogel for bearing applications|

EP1595534A1|2004-05-13|2005-11-16|Universiteit Utrecht Holding B.V.|Gel composition comprising charged polymers|

US7651702B2|2004-05-20|2010-01-26|Mentor Corporation|Crosslinking hyaluronan and chitosanic polymers|

CA2567532C|2004-05-20|2013-10-01|Mentor Corporation|Methods for making injectable polymer hydrogels|

CA2572603C|2004-06-29|2013-01-15|Biocure, Inc.|Spinal disc nucleus pulposus implant|

US7244443B2|2004-08-31|2007-07-17|Advanced Cardiovascular Systems, Inc.|Polymers of fluorinated monomers and hydrophilic monomers|

WO2006026412A2|2004-08-31|2006-03-09|Vnus Medical Technologies, Inc.|Apparatus and material composition for permanent occlusion of a hollow anatomical structure|

DE102004045224B4|2004-09-17|2010-12-30|Thilo Dr. Fliedner|support prosthesis|

US20060074182A1|2004-09-30|2006-04-06|Depuy Products, Inc.|Hydrogel composition and methods for making the same|

JP4959583B2|2005-01-25|2012-06-27|タイコヘルスケアグループリミテッドパートナーシップ|Structure for permanent occlusion of hollow anatomical structures|

US20080227696A1|2005-02-22|2008-09-18|Biosurface Engineering Technologies, Inc.|Single branch heparin-binding growth factor analogs|

US20060222596A1|2005-04-01|2006-10-05|Trivascular, Inc.|Non-degradable, low swelling, water soluble radiopaque hydrogel polymer|

KR100748348B1|2005-07-19|2007-08-09|한국원자력연구원|Method for the preparation of hydrogels for wound dressing using radiation irradiation|

US9101436B2|2005-10-21|2015-08-11|Ada Foundation|Dental and endodontic filling materials and methods|

US9259439B2|2005-10-21|2016-02-16|Ada Foundation|Dual-phase cement precursor systems for bone repair|

US8048350B2|2005-10-31|2011-11-01|Scott Epstein|Structural hydrogel polymer device|

WO2007059605A1|2005-11-04|2007-05-31|Bio Syntech Canada Inc.|Composition and method for efficient delivery of nucleic acids to cells using chitosan|

US20070149641A1|2005-12-28|2007-06-28|Goupil Dennis W|Injectable bone cement|

EP1996243B1|2006-01-11|2014-04-23|HyperBranch Medical Technology, Inc.|Crosslinked gels comprising polyalkyleneimines, and their uses as medical devices|

EP1979018B1|2006-02-03|2013-08-07|Tissuemed Limited|Tissue-adhesive materials|

US20070184087A1|2006-02-06|2007-08-09|Bioform Medical, Inc.|Polysaccharide compositions for use in tissue augmentation|

FR2897775B1|2006-02-24|2013-05-03|Elisabeth Laugier|BIOMATERIAU, INJECTABLE IMPLANT COMPRISING IT, PROCESS FOR PREPARING THE SAME AND USES THEREOF|

US20090018575A1|2006-03-01|2009-01-15|Tissuemed Limited|Tissue-adhesive formulations|

US9017361B2|2006-04-20|2015-04-28|Covidien Lp|Occlusive implant and methods for hollow anatomical structure|

US7820172B1|2006-06-01|2010-10-26|Biosurface Engineering Technologies, Inc.|Laminin-derived multi-domain peptides|

EP2046350A4|2006-06-22|2011-09-14|Biosurface Eng Tech Inc|Composition and method for delivery of bmp-2 amplifier/co-activator for enhancement of osteogenesis|

US9028859B2|2006-07-07|2015-05-12|Advanced Cardiovascular Systems, Inc.|Phase-separated block copolymer coatings for implantable medical devices|

EP2046288B1|2006-07-14|2013-07-03|FMC Biopolymer AS|Hydrogels containing low molecular weight alginates and biostructures made therefrom|

CN101578520B|2006-10-18|2015-09-16|哈佛学院院长等|Based on formed pattern porous medium cross flow and through biometric apparatus, and preparation method thereof and using method|

CA2676294C|2007-02-09|2014-10-21|Novartis Ag|Cross-linkable polyionic coatings for contact lenses|

EP2136855A2|2007-03-20|2009-12-30|Boston Scientific Scimed, Inc.|Urological medical devices for release of prostatically beneficial therapeutic agents|

CA2687284A1|2007-03-20|2008-09-25|Boston Scientific Limited|Urological medical devices for release of therapeutic agents|

MX2009012103A|2007-05-11|2010-02-18|Aeris Therapeutics Llc|Lung volume reduction therapy using crosslinked non-natural polymers.|

CN105943208B|2007-06-25|2019-02-15|微仙美国有限公司|Self-expanding prosthesis|

GB0715514D0|2007-08-10|2007-09-19|Tissuemed Ltd|Coated medical devices|

US8663309B2|2007-09-26|2014-03-04|Trivascular, Inc.|Asymmetric stent apparatus and method|

US8066755B2|2007-09-26|2011-11-29|Trivascular, Inc.|System and method of pivoted stent deployment|

US8226701B2|2007-09-26|2012-07-24|Trivascular, Inc.|Stent and delivery system for deployment thereof|

EP2194921B1|2007-10-04|2018-08-29|TriVascular, Inc.|Modular vascular graft for low profile percutaneous delivery|

US7919542B2|2007-11-12|2011-04-05|Zimmer Spine, Inc.|Phase separated, branched, copolymer hydrogel|

US8328861B2|2007-11-16|2012-12-11|Trivascular, Inc.|Delivery system and method for bifurcated graft|

US8083789B2|2007-11-16|2011-12-27|Trivascular, Inc.|Securement assembly and method for expandable endovascular device|

US8668863B2|2008-02-26|2014-03-11|Board Of Regents, The University Of Texas System|Dendritic macroporous hydrogels prepared by crystal templating|

US20090220578A1|2008-02-28|2009-09-03|Depuy Products, Inc.|Hydrogel composition and method for making the same|

CN102132398B|2008-03-21|2015-01-28|哈佛学院院长等|Self-aligned barrier layers for interconnects|

KR101510785B1|2008-03-27|2015-04-10|프레지던트 앤드 펠로우즈 오브 하바드 칼리지|Cotton thread as a low-cost multi-assay diagnostic platform|

AU2009228012A1|2008-03-27|2009-10-01|President And Fellows Of Harvard College|Paper-based microfluidic systems|

WO2009121038A2|2008-03-27|2009-10-01|President And Fellows Of Harvard College|Shaped films of hydrogels fabricated using templates of patterned paper|

CN103203210A|2008-03-27|2013-07-17|哈佛学院院长等|Paper-based Cellular Arrays|

KR101561718B1|2008-03-27|2015-10-19|프레지던트 앤드 펠로우즈 오브 하바드 칼리지|Three-dimensional microfluidic devices|

MY144571A|2008-04-24|2011-10-14|Univ Malaya|Extracellular scaffold|

US7833384B2|2008-06-30|2010-11-16|Weyerhaeuser Nr Company|Method for making fiber having biodegradable superabsorbent particles attached thereto|

US8641869B2|2008-06-30|2014-02-04|Weyerhaeuser Nr Company|Method for making biodegradable superabsorbent particles|

US7959762B2|2008-06-30|2011-06-14|Weyerhaeuser Nr Company|Method for making biodegradable superabsorbent particles|

US8101543B2|2008-06-30|2012-01-24|Weyerhaeuser Nr Company|Biodegradable superabsorbent particles|

US20090326180A1|2008-06-30|2009-12-31|Weyerhaeuser Co.|Biodegradable Superabsorbent Particles Containing Cellulose Fiber|

US8084391B2|2008-06-30|2011-12-27|Weyerhaeuser Nr Company|Fibers having biodegradable superabsorbent particles attached thereto|

US20090325797A1|2008-06-30|2009-12-31|Weyerhaeuser Co.|Biodegradable Superabsorbent Particles|

DE102008053892A1|2008-10-30|2010-05-06|Fachhochschule Gelsenkirchen|Medical implant with biofunctionalized surface|

AU2010221102A1|2009-03-06|2011-09-29|President And Fellows Of Harvard College|Microfluidic, electrochemical devices|

KR101770537B1|2009-10-23|2017-08-22|프레지던트 앤드 펠로우즈 오브 하바드 칼리지|Self-aligned barrier and capping layers for interconnects|

JP2013509963A|2009-11-09|2013-03-21|スポットライトテクノロジーパートナーズエルエルシー|Fragmented hydrogel|

EP2498763A4|2009-11-09|2015-10-07|Spotlight Technology Partners Llc|Polysaccharide based hydrogels|

AU2010340067B2|2009-12-15|2015-03-19|Incept, Llc|Implants and biodegradable fiducial markers|

CN102821861B|2010-02-03|2015-03-25|哈佛大学校长及研究员协会|Devices and methods for multiplexed assays|

US9232805B2|2010-06-29|2016-01-12|Biocure, Inc.|In-situ forming hydrogel wound dressings containing antimicrobial agents|

AP2012006604A0|2010-07-02|2012-12-31|Indian Council Of Agriculture Res|Novel superabsorbents and the method of obtaining the same|

WO2012048283A1|2010-10-08|2012-04-12|Board Of Regents, The University Of Texas System|One-step processing of hydrogels for mechanically robust and chemically desired features|

EP2624874A4|2010-10-08|2014-04-02|Univ Texas|Anti-adhesive barrier membrane using alginate and hyaluronic acid for biomedical applications|

EP2643020A4|2010-11-26|2014-11-12|Univ Witwatersrand Jhb|A drug delivery device|

KR101303284B1|2011-04-06|2013-09-04|한국원자력연구원|Hydrogel having hyaluronic acid and condroitin sulfate and manufacturing method thereof|

CA2835427A1|2011-05-11|2012-11-15|Microvention, Inc.|Device for occluding a lumen|

CA2837303C|2011-05-26|2019-08-20|Cartiva, Inc.|Tapered joint implant and related tools|

WO2013010045A1|2011-07-12|2013-01-17|Biotime Inc.|Novel methods and formulations for orthopedic cell therapy|

AU2014240353A1|2013-11-12|2015-05-28|Covidien Lp|Degradable implantable battery|

US8968927B2|2011-07-15|2015-03-03|Covidien Lp|Degradable implantable battery|

US8968926B2|2011-07-15|2015-03-03|Covidien Lp|Degradable implantable galvanic power source|

US9205150B2|2011-12-05|2015-12-08|Incept, Llc|Medical organogel processes and compositions|

US8992595B2|2012-04-04|2015-03-31|Trivascular, Inc.|Durable stent graft with tapered struts and stable delivery methods and devices|

US9498363B2|2012-04-06|2016-11-22|Trivascular, Inc.|Delivery catheter for endovascular device|

KR101766679B1|2012-12-11|2017-08-09|보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템|Hydrogel membrane for adhesion prevention|

WO2014144364A1|2013-03-15|2014-09-18|Children's Medical Center Corporation|Gas-filled stabilized particles and methods of use|

CN103446897B|2013-09-13|2015-03-11|天津工业大学|Chemical and ionic cross-linked alginate hydrogel flat membrane for filtration and preparation method thereof|

DK3079750T3|2013-12-12|2020-07-13|Hollister Inc|EXCLUSIVE CATHETRES|

US9907663B2|2015-03-31|2018-03-06|Cartiva, Inc.|Hydrogel implants with porous materials and methods|

EP3277228B1|2015-03-31|2020-01-15|Cartiva, Inc.|Carpometacarpalimplants|

CA2981074A1|2015-04-14|2016-10-20|Cartiva, Inc.|Tooling for creating tapered opening in tissue and related methods|

KR101624511B1|2016-01-15|2016-05-26|전남대학교산학협력단|Antiadhesion coposition and comprising antiadhesion agent preparing method thereof|

CN105797685A|2016-05-09|2016-07-27|江苏大学|Preparation method of sodium alginate-graphene oxide macroscopic sphere composite material|

EP3494146A1|2016-12-23|2019-06-12|Galderma Research & Development|Double crosslinked glycosaminoglycans|

BR112019002287A2|2016-08-03|2019-06-18|Centre Nat Rech Scient|cross-linked glycosaminoglycans, method for cross-linking a first grafted glycosaminoglycan with a diol functional moiety having a diol moiety and a second glycosaminoglycan grafted with a boronate hemiester, use of a boronate hemiester, and, polymer composition.|

法律状态:
2002-04-26| STCF| Information on status: patent grant|Free format text: PATENTED CASE |

2004-03-16| CC| Certificate of correction|

2005-09-27| FPAY| Fee payment|Year of fee payment: 4 |

2009-09-28| FPAY| Fee payment|Year of fee payment: 8 |

2013-10-16| FPAY| Fee payment|Year of fee payment: 12 |

优先权:

申请号 | 申请日 | 专利标题

US08/679,609|US6060534A|1996-07-11|1996-07-11|Medical devices comprising ionically and non-ionically crosslinked polymer hydrogels having improved mechanical properties|

US09/496,709|US6184266B1|1996-07-11|2000-02-02|Medical devices comprising cross-linked hydrogels having improved mechanical properties|

US09/757,396|US6387978B2|1996-07-11|2001-01-08|Medical devices comprising ionically and non-ionically crosslinked polymer hydrogels having improved mechanical properties|US09/757,396| US6387978B2|1996-07-11|2001-01-08|Medical devices comprising ionically and non-ionically crosslinked polymer hydrogels having improved mechanical properties|

[返回顶部]